[:pb]Efficacy of the 7-chloro-4-(3-hydroxy-benzilidenehydrazo)quinoline derivative against infection caused by Leishmania amazonensis[:]

[:pb]Authors: Antinarelli, L. M. R. ; De Souza, M. V. N.; Coelho, E. A. F. ; Lima, W. P. ; Coimbra, E. S.
Source: Sociedade Brasileira De Medicina Tropical, v. 53, p. 1-5, 2020
Publisher: Revista da Sociedade Brasileira de Medicina Tropical


Abstract

Introduction: The drugs currently available for leishmaniasis treatment have major limitations.

Methods: In vitro and in vivo studies were performed to evaluate the effect of a quinoline derivative, Hydraqui (7-chloro-4-(3-hydroxy-benzilidenehydrazo)quinoline, against Leishmania amazonensis. In silico analyses of absorption, distribution, metabolism, excretion, and toxicity (ADMET) parameters were performed.

Results: Hydraqui showed significant in vitro anti-amastigote activity. Also, Hydraqui-treated mice exhibited high efficacy in lesion size (48.3%) and parasitic load (93.8%) reduction, did not cause hepatic and renal toxicity, and showed appropriate ADMET properties.

Conclusions: Hydraqui presents a set of satisfactory criteria for its application as an antileishmanial agent


Keywords: leishmania amazonensis, quinoline, chemotherapy, cutaneous leishmaniasis, toxicity

Document Type: Research Article

DOI: 10.1590/0037-8682-0091-2020

Publication date: 14 de abril de 2020[:]

Compartilhar publicação

Facebook
Twitter
Email
LinkedIn
WhatsApp

Deixe seu comentário

Compartilhar

Sobre a SSCDT

Nosso grupo de pesquisa está situado em Farmanguinhos e atualmente é o maior laboratório farmacêutico oficial vinculado ao Ministério da Saúde. Farmanguinhos produz mais de um bilhão de medicamentos por ano para os programas estratégicos do Governo Federal, além de atender demandas emergenciais no Brasil e no exterior.

posts Recentes